Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
1999 1
2000 5
2001 2
2002 3
2003 5
2004 9
2005 8
2006 5
2007 8
2008 2
2009 10
2010 12
2011 13
2012 1
2013 1
2014 3
2015 5
2016 1
2017 4
2018 2
2021 1
2022 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Thatcher N, et al. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Free article. Clinical Trial.
Catumaxomab: a bispecific trifunctional antibody.
Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Sebastian M, et al. Among authors: schmittel a. Drugs Today (Barc). 2009 Aug;45(8):589-97. Drugs Today (Barc). 2009. PMID: 19927225 Review.
Second-line therapy for small-cell lung cancer.
Schmittel A. Schmittel A. Expert Rev Anticancer Ther. 2011 Apr;11(4):631-7. doi: 10.1586/era.11.7. Expert Rev Anticancer Ther. 2011. PMID: 21504329 Review.
The Diagnosis, Treatment, and Aftercare of Cervical Carcinoma.
Beckmann MW, Stuebs FA, Vordermark D, Koch MC, Horn LC, Fehm T; Collaborators. Beckmann MW, et al. Dtsch Arztebl Int. 2021 Nov 26;118(47):806-812. doi: 10.3238/arztebl.m2021.0352. Dtsch Arztebl Int. 2021. PMID: 34755595 Free PMC article.
Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N, Roeper J, Velthaus JL, Raspe M, Olive E, Schmittel A, Schmidt B, Wasilewski D, Onken J, Lüders H, Witzenrath M, Senger C, Böhmer D, Loges S, Griesinger F, Modest DP, Grohé C. Frost N, et al. Among authors: schmittel a. Lung Cancer. 2022 Aug;170:165-175. doi: 10.1016/j.lungcan.2022.06.017. Epub 2022 Jul 2. Lung Cancer. 2022. PMID: 35803041
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. Schmittel A, et al. Ann Oncol. 2011 Aug;22(8):1798-804. doi: 10.1093/annonc/mdq652. Epub 2011 Jan 25. Ann Oncol. 2011. PMID: 21266516 Free article. Clinical Trial.
Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group.
Kivelä TT, Piperno-Neumann S, Desjardins L, Schmittel A, Bechrakis N, Midena E, Leyvraz S, Zografos L, Grange JD, Ract-Madoux G, Marshall E, Damato B, Eskelin S. Kivelä TT, et al. Among authors: schmittel a. Am J Ophthalmol. 2016 Aug;168:217-226. doi: 10.1016/j.ajo.2016.06.002. Epub 2016 Jun 11. Am J Ophthalmol. 2016. PMID: 27296487
96 results